Trial Profile

Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camptothecin (Primary) ; Bevacizumab; Fluorouracil; Folic acid; Oxaliplatin
Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Sponsors Cerulean Pharma; NewLink Genetics Corporation

Most Recent Events

21 Feb 2019 Status changed from active, no longer recruiting to discontinued.
18 Apr 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.
18 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com